Jolavi Tablet contains Midodrine 2.5 mg, an alpha-1 adrenergic agonist indicated primarily for the treatment of symptomatic orthostatic hypotension. Midodrine acts by stimulating alpha-1 adrenergic receptors on the vascular smooth muscle, leading to vasoconstriction and an increase in peripheral vascular resistance, thereby elevating blood pressure. This pharmacological action helps alleviate symptoms such as dizziness, lightheadedness, and syncope associated with low blood pressure upon standing. Jolavi is typically prescribed for patients who experience chronic orthostatic hypotension due to autonomic dysfunction, including conditions like diabetic autonomic neuropathy, multiple system atrophy, or other neurogenic causes. The recommended dosage should be individualized based on patient response and tolerance, with careful monitoring to avoid supine hypertension, a known adverse effect. Common side effects may include piloerection, pruritus, urinary retention, and paresthesia. Jolavi should be used cautiously in patients with severe heart disease, renal impairment, or those on concurrent antihypertensive therapy. It is contraindicated in patients with supine hypertension and should not be administered within four hours of bedtime to minimize the risk of elevated nocturnal blood pressure. Regular blood pressure monitoring and clinical assessment are essential to ensure therapeutic efficacy and safety during treatment with Jolavi Tablet.